Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients

被引：0

作者：

Sellem, B. ^{[1
]}

Abdi, B. ^{[2
]}

Peytavin, G. ^{[3
]}

Tubiana, R. ^{[1
]}

Valantin, M. -A. ^{[1
]}

Seang, S. ^{[1
]}

Schneider, L. ^{[1
]}

Faycal, A. ^{[1
]}

Soulie, C. ^{[2
]}

Marcelin, A. -G. ^{[2
]}

Katlama, C. ^{[1
]}

Pourcher, V. ^{[1
]}

Palich, R. ^{[1
]}

机构：

[1] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Infect Dis Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France

[2] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Virol Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France

[3] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept,IAME,INSERM,UMRS 1137, Paris, France

来源：

HIV MEDICINE | 2021年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PE2/23

引用

页码：90 / 91

页数：2

共 50 条

[1] Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Johnson, M.
Taylor, S.
Wei, X.
Collins, S.
Martin, H.
HIV MEDICINE, 2019, 20 : 40 - 40
[2] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
Kityo, C.
Koenig, E.
Avihingsanon, A.
Supparatpinyo, K.
DeJesus, E.
Wang, H.
Quirk, E.
Martin, H.
Elliott, C.
Makadzange, T.
HIV MEDICINE, 2018, 19 : S30 - S30
[3] Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a single centre in Portugal
Gorgulho, A.
Vaz-Pinto, I.
Santos, C.
Guimaraes, M.
Castro, V.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 103 - 104
[4] Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
Sellem, Baptiste
Abdi, Basma
Le, Minh
Tubiana, Roland
Valantin, Marc-Antoine
Seang, Sophie
Schneider, Luminita
Faycal, Antoine
Peytavin, Gilles
Soulie, Cathia
Marcelin, Anne-Genevieve
Katlama, Christine
Pourcher, Valerie
Palich, Romain
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (04):
[5] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
Truong, David
Yi, Shana
Wiesmann, Christina
Conway, Brian
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 181 - 181
[6] Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
Proud, E.
Murphy, C.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 46 - 47
[7] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
Acosta, R.
Andreatta, K.
D'Antoni, M.
Collins, S.
Martin, H.
White, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
[8] Pharmacokinetics, safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV
Zhang, H.
Martin, H.
Lin, L.
Davis, M.
Huang, H.
Xiao, D.
Arora, P.
Avihingsanon, A.
Koenig, E.
Palaparthy, R.
Girish, S.
Marathe, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
[9] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
Hill, L.
Momper, J.
Abulhosn, K.
Ballard, C.
Young, M.
HIV MEDICINE, 2019, 20 : 81 - 81
[10] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
Sax, P. E.
Rockstroh, J.
Luetkemeyer, A.
Yasdanpanah, Y.
Ward, D.
Trottier, B.
Rieger, A.
Liu, H.
Acosta, R.
Collins, S. E.
Brainard, D.
Martin, H.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4

← 1 2 3 4 5 →